RxDoctor Payments DataLook up a doctor →

Christopher Chay, MD

Hematology & Oncology · Asheville, NCNPI 1699764878

Payments from drug & device makers

$1,458,525in general payments, 2019–2025

Across 645 payments — averaging $2261.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$537K
  • Epizyme, Inc.$164K
  • Genentech, Inc.$158K
  • Ipsen Bioscience Inc.$93K
  • Merck$86K
  • Daiichi Sankyo Inc.$78K
  • plus $343K from 54 others
$18,374in research payments, 2019–2025

Across 6 payments — averaging $3062.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$18K

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly16$536,621
Epizyme, Inc.153$163,546
Genentech, Inc.43$158,387
Ipsen Bioscience Inc.29$92,635
Merck36$85,868
Daiichi Sankyo Inc.43$78,466
Beigene, Ltd.22$66,915
Amgen10$63,945
Morphosys AG13$54,700
Novartis39$50,761
AstraZeneca(2 entities)26$39,470
Eisai Inc.22$21,605
F. Hoffmann-la Roche AG4$13,150
E.r. Squibb & Sons, L.L.C.17$10,518
Incyte Corporation7$7,749
Takeda Pharmaceuticals U.S.A., Inc.16$4,639
Morphosys, US Inc.2$2,017
Seagen Inc.4$1,652
Caris MPI, Inc.3$1,136
Rigel Pharmaceuticals, Inc.1$1,024
AbbVie9$902
Johnson & Johnson(2 entities)25$604
Acera Surgical, Inc.1$148
Genentech USA, Inc.7$125
Beigene USA, Inc.7$125
Astellas Pharma US Inc6$119
Bayer5$118
Pfizer7$117
Boehringer Ingelheim5$114
Bristol Myers Squibb5$114
Deciphera Pharmaceuticals Inc.4$105
Sanofi3$92
GSK5$86
Beone Medicines USA, Inc.4$78
Gilead(2 entities)4$72
Servier Pharmaceuticals LLC3$64
Exelixis Inc.3$54
Stemline Therapeutics Inc.2$54
Puma Biotechnology, Inc.3$42
Taiho Oncology, Inc.2$41
Jazz Pharmaceuticals Inc.2$41
Tactile Systems Technology Inc2$38
Lilly USA, LLC2$36
Sobi, Inc2$36
Acrotech Biopharma Inc.2$36
AVEO Pharmaceuticals, Inc.2$35
Organon1$31
G1 Therapeutics, Inc.1$23
Pharmaessentia USA Corporation1$22
Regeneron Healthcare Solutions, Inc.1$22
Mirati Therapeutics, Inc.1$21
Genmab U.S., Inc.1$21
Tersera Therapeutics LLC1$20
Alnylam Pharmaceuticals Inc.1$19
Boston Scientific1$18
EMD Serono, Inc.1$18
Recordati_rare_diseases_inc.1$17
ADC Therapeutics America, Inc.1$17
Avyxa Pharma, LLC1$16
Karyopharm Therapeutics Inc.1$15

How this compares

$1,458,525 in reported general payments places this provider in the 90th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina →

Medicare billing

Part B allowed, 2024
$4,003,410
Medicare patients
1,082
Services billed
130,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Asheville

See the full list for North Carolina →

Where these figures come from

Is this you, or does something look wrong? →